Ebola virus vaccination elicits Ebola virus–specific immune responses without substantial cross-reactivity to other filoviruses

The Janssen Ebola virus (EBOV) vaccine consists of the adenovirus type 26 vector encoding the EBOV glycoprotein (GP) (Ad26.ZEBOV) and the modified vaccinia Ankara (MVA) vector encoding GP from EBOV, Sudan virus, and Marburg virus and nucleoprotein from Tai Forest virus (MVA-BN-Filo) administered 8 weeks later. We conducted a systems immunology analysis of antibody-mediated and cellular immune responses induced after two immunizations with either vaccine used first. The response to vaccination was EBOV GP specific and defined by high antibody binding, Fc effector, and neutralizing responses with CD4 T cell responses also contributing. The vaccine-induced antibody profile did not distinguish people living with or without HIV-1. Samples from 48 survivors and 121 contacts from the 2007 Ugandan Bundibugyo virus epidemic also showed minimal cross-reactivity to other filovirus proteins after infection and exposure. The lack of cross-reactivity suggests that different multivalent vaccine candidates are required to provide broad protection across filoviruses.

Authors

Institutions

Publication Details

Journal
Science Translational Medicine
Published
2025-04-02
DOI
https://doi.org/10.1126/scitranslmed.adq2496
Citations
4
Primary Topic
Viral Infections and Outbreaks Research
Type
article
Field-Weighted Citation Impact
5.58
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ebola virus vaccination elicits Ebola virus–specific immune responses without substantial cross-reactivity to other filoviruses

Thembi Mdluli, Betty Mwesigwa, Bethany L. Dearlove, Mélanie Merbah et al.
4 citations
Science Translational Medicine
Viral Infections and Outbreaks Research
5.58
article

Ebola virus vaccination elicits Ebola virus–specific immune responses without substantial cross-reactivity to other filoviruses

Thembi Mdluli, Betty Mwesigwa, Bethany L. Dearlove, Mélanie Merbah, Aljawharah Alrubayyi, Cynthia Robinson, Michael D. Barrera, Zhanna Shubin, Gideon Akintunde, Bradley Beckman, Dominic Paquin‐Proulx, Michael A. Eller, Ilesh Vinodrai Jani, Margaret C. Costanzo, Chelsea McLean, Leigh Anne Eller, Steven A. Kwilas, Fred Sawe, Julie A. Ake, Suzanne E. Wollen-Roberts, Kerstin Lühn, Michael Iroezindu, Nyanda Elias Ntinginya, Morgane Rolland, Kristopher Paolino, Hannah Kibuuka, Jacob Boeckelman, Shayla Duncan, Merlin L. Robb, Jay W. Hooper, Josphat Kosgei, Hongjun Bai, Joel Mwakisisile, Yifan Li, Dohoon Kim, Daniel Curtis, Edna Viegas, Lucy Ward, Janet Nyawira Oyieko, Pallavi Thapa
article en
4 citations

Abstract

The Janssen Ebola virus (EBOV) vaccine consists of the adenovirus type 26 vector encoding the EBOV glycoprotein (GP) (Ad26.ZEBOV) and the modified vaccinia Ankara (MVA) vector encoding GP from EBOV, Sudan virus, and Marburg virus and nucleoprotein from Tai Forest virus (MVA-BN-Filo) administered 8 weeks later. We conducted a systems immunology analysis of antibody-mediated and cellular immune responses induced after two immunizations with either vaccine used first. The response to vaccination was EBOV GP specific and defined by high antibody binding, Fc effector, and neutralizing responses with CD4 T cell responses also contributing. The vaccine-induced antibody profile did not distinguish people living with or without HIV-1. Samples from 48 survivors and 121 contacts from the 2007 Ugandan Bundibugyo virus epidemic also showed minimal cross-reactivity to other filovirus proteins after infection and exposure. The lack of cross-reactivity suggests that different multivalent vaccine candidates are required to provide broad protection across filoviruses.

Science Translational MedicineVol. 17(792)
Henry M. Jackson Foundation (US), United States Department of Defense (US), SUNY Upstate Medical University (US), Makerere University Walter Reed Project (UG), United States Army Medical Research Institute of Infectious Diseases (US), United States Army Medical Research Directorate - Africa (KE), African Field Epidemiology Network (NG), Jackson Foundation (US), National Directorate of Geology (MZ), Janssen (Netherlands) (NL), National Institute for Medical Research (TZ), Walter Reed Army Institute of Research (US)
Good health and well-being
Openalex Percentile: Top 4%
Viral Infections and Outbreaks Research
5.58
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.